A photo of Charles Quinn.

Medical Director, Erythrocyte Diagnostic Laboratory

Medical Director, Pediatric Sickle Cell Program

Professor, UC Department of Pediatrics



Board Certified

Best Doctors logo

My Biography & Research


Dr. Quinn conducts patient-oriented and translational research in sickle cell disease and thalassemia. He is the medical director of the Pediatric Sickle Cell Disease Program and the medical director of the Erythrocyte Diagnostic Laboratory at Cincinnati Children’s Hospital. He is also the medical director of the Ohio Department of Health Regional Sickle Cell Services Program – Region 1.

Clinical Interests

Sickle cell disease; thalassemia; hemoglobinopathies; genetics of hemoglobinopathies; anemia; autoimmune hemolytic anemia; disorders of red blood cells; iron overload and iron chelation; chronic transfusion therapy; hereditary spherocytosis (HS); hereditary xerocytosis (HX); immune thrombocytopenia (ITP).

Research Interests

Identifying the causes of the cardiomyopathy and nephropathy of sickle cell disease and identifying new treatments for these complications; direct measurement of red blood cell turnover (rate of hemolysis); MRI methods for the quantitation of tissue iron; new agents for immune thrombocytopenia (ITP).

Academic Affiliation

Professor, UC Department of Pediatrics


Cancer and Blood Diseases, Sickle Cell and Hemoglobin Disorders, Cerebrovascular, Hematology, Cancer and Blood Diseases

My Locations

My Education

MD: University of Texas Southwestern Medical Center, Dallas, TX, 1994.

MS: University of Texas Southwestern Medical Center, Dallas, TX, 2008.

Residency & Chief Residency: Children's Medical Center Dallas, Dallas, TX; University of Texas Southwestern Medical Center, Dallas, TX, 1998.

Fellowship: Children's Medical Center Dallas, Dallas, TX; University of Texas Southwestern Medical Center, Dallas, TX, 2001.

Certifications: Pediatrics, 1998; Pediatric Hematology-Oncology, 2002.

My Publications

Acceptability and Feasibility of a Disease-specific Patient Portal in Adolescents With Sickle Cell Disease. Kidwell, KM; Peugh, J; Westcott, E; Nwankwo, C; Britto, MT; Quinn, CT; Crosby, LE. Journal of Pediatric Hematology/Oncology. 2019; 41:561-567.

Hydroxyurea for children with sickle cell anemia: Prescribe it early and often. Ware, RE; McGann, PT; Quinn, CT. Pediatric Blood and Cancer. 2019; 66.

Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia. McGann, PT; Niss, O; Dong, M; Marahatta, A; Howard, TA; Mizuno, T; Lane, A; Kalfa, TA; Malik, P; Quinn, CT; et al. American Journal of Hematology. 2019; 94:871-879.

Hemoglobin Southampton complicated by cerebral ischemia, moyamoya, and hydroxyurea-induced methemoglobinemia. Boucher, AA; Gurunathan, A; Taylor, JM; Ricci, KW; Vadivelu, S; Quinn, CT. American Journal of Hematology. 2019; 94:949-954.

The Case for Pharmacogenetics-Guided Prescribing of Codeine in Children. Gammal, RS; Caudle, KE; Quinn, CT; Wang, WC; Gaedigk, A; Prows, CA; Haidar, CE; Taylor, AK; Klein, TE; Sangkuhl, K; et al. Clinical Pharmacology and Therapeutics. 2019; 105:1300-1302.

Abnormal submaximal cardiopulmonary exercise parameters predict impaired peak exercise performance in sickle cell anemia patients. Powell, AW; Alsaied, T; Niss, O; Fleck, RJ; Malik, P; Quinn, CT; Mays, WA; Taylor, MD; Chin, C. Pediatric Blood and Cancer. 2019; 66.

A Preliminary Investigation of the Psychometric Properties of PROMIS (R) Scales in Emerging Adults With Sickle Cell Disease. Hildenbrand, AK; Quinn, CT; Mara, CA; Peugh, JL; McTate, EA; Britto, MT; Crosby, LE. Health Psychology. 2019; 38:386-390.

Point-of-care screening for sickle cell disease in low-resource settings: A multi-center evaluation of HemoTypeSC, a novel rapid test. Steele, C; Sinski, A; Asibey, J; Hardy-Dessources, M; Elana, G; Brennan, C; Odame, I; Hoppe, C; Geisberg, M; Serrao, E; et al. American Journal of Hematology. 2019; 94:39-45.

Silent cerebral infarction: supply and demand. Quinn, CT. Blood. 2018; 132:1632-1634.

Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia. Gruppo, RA; Malan, D; Kapocsi, J; Nemes, L; Hay, CR M; Boggio, L; Chowdary, P; Tagariello, G; von Drygalski, A; Hua, F; et al. Journal of Thrombosis and Haemostasis. 2018; 16:1984-1993.